Perspectives for cytokine antagonist therapy in COPD
Related Experiment Videos
1Netherlands Asthma Foundation, P.O. Box 5, 3830AA, Leusden, The Netherlands. deboer.pim.hetnet.nl
Abstract:
Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease associated with progressive airflow limitation. The main risk factor is tobacco smoking. Anti-inflammatory therapies (e.g. corticosteroids) are based on those developed initially for asthma. In contrast to asthma, they are rather ineffective in improving chronic symptoms and reducing inflammation and lung function decline. Specific drugs need to be developed directed against this chronic inflammation, thereby preventing lung tissue damage. Cytokine antagonists for tumour necrosis factor alpha, interleukin 8 receptor, interleukin 1, and specific signal transduction inhibitors have proven to be effective for other inflammatory diseases. Their efficacy for COPD therapy has yet to be demonstrated.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...